Albion News

Albion-NewHome.jpg We've recently moved offices! After 10 years in Bank, we've moved to a new office in Farringdon! Our new address is: 1 Benjamin Street, London, EC1M 5QL - our telephone number isn’t changing. read more
Will Fraser-Allen
After more than 23 years as Managing Director, and then Managing Partner of Albion Capital, Patrick Reeve has become Chairman of the business in a newly created role, with Will Fraser-Allen moving to Managing Partner, and Andrew Elder becoming Deputy Managing Partner. From April, Patrick Reeve will chair the Albion and OLIM boards and continue to be involved in directing the strategy of the business, whilst maintaining key relationships across the Albion Capital VCT range, Albion Community Power and the UCL Technology Fund. Patrick joined Close Brothers in 1989, established Close Ventures in... read more
Orchard Therapeutics, a commercial-stage biopharmaceutical company, presented their two-year follow-up data in 20 patients from the registrational trial evaluating OTL-101, aimed at treating those with adenosine deaminase deficiency (ADA-SCID). They achieved a 100% Overall Survival and 100% Event Free Survival in Patients Treated with OTL-101; compared to 88% OS and 56% EvFS with Historical HSCT Overall at 24 months ADA-SCID is a rare, life-threatening, inherited disease caused by mutations in the ADA gene. Patients with ADA-SCID are unable to fight off and frequently succumb to complications... read more
2018 2019 Securities Note
The documents relating to the Offers are now avaible on the Current Offers page read more
OLIM Charity Conference 2019
Following the success of the OLIM Charity Conference in 2018 we are delighted to invite all charity trustees and those interested in the sector to join us at this year’s event. The 2018 OLIM Charity Conference attracted over 150 Trustees from a wide variety of charities and the feedback on the whole event was very positive. 2019 OLIM Charity Conference – ‘Charity Trustees in a Changing World’ Date: Thursday 6 June 2019 Venue: The RAC, 89 Pall Mall, St James’s, London SW1Y 5HS Time 10:00 – 14:30 If you would like to attend the next event, or need more information about OLIM, please email us at... read more
FT Adviser
Will Fraser-Allen, deputy managing partner of Albion writes in FT Adviser To read the full article please click here read more
The fundraising is expected to target £6 million for each of the six Albion VCTs: Albion Venture Capital Trust PLC, Albion Development VCT PLC, Albion Enterprise VCT PLC, Albion Technology & General VCT PLC, Crown Place VCT PLC and Kings Arms Yard VCT PLC. The Albion VCTs’ combined portfolios have a value of approximately £400 million*, diversified across approximately 60 businesses. The planned top up offers reflect Albion Capital’s confidence in an exciting pipeline of investment opportunities in sectors with long-term growth potential. Over the last five years the Albion VCTs have... read more
Growth Investor of the Year Award
Albion is delighted to have won the award for GROWTH INVESTOR OF THE YEAR 2018   Growth Investor of the Year Award   This is the highest accolade for investment providers, and recognises those demonstrating the best investment performance, the best impact on an investee company, the most innovation in product development, and the most engagement in adviser outreach. The Finalists were: Albion Capital Calculus Capital Deepbridge Capital Mercia Fund Managers MMC Ventures Octopus Investments Oxford Capital Seneca Congratulations to everyone. read more
Dysis Imaging
DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors. In addition, Michael Gioffredi was appointed as Chief Commercial Officer. Former CEO Alastair Atkinson will remain with the company and assume the role of Chief Operating Officer. “We believe that Mr. Hammers and Mr. Gioffredi have the right leadership experience and knowledge of the U.S. medical device market to establish DYSIS as the leader in Colposcopy. On behalf of... read more
Hazy AI
Hazy -  has been listed by Forbes as one of the Top 15 European Machine Learning companies to watch. Hazy is an AI spin-out from UCL and is one of the businesses invested in by the UCLTechnology Fund which is managed by Albion in collaboration with UCLB. Hazy is a platform that helps businesses identify and anonymise personal data in large datasets whilst maintaining its utility, enabling Hazy’s customers to remain GDPR compliant. Hazy uses ML techniques to capture trends, patterns, and correlations in data in a single, compressed model, and then use this model to generate synthetic data that... read more

Pages